Browse Studies — Arctuva

Phase 1

A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)

The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mes…

Mesial Temporal Lobe Epilepsy

Estimated

~$10 – $8,750

UniQure Biopharma B.V.NCT06063850

Phase 3

A Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), …

Mesial Temporal Lobe Epilepsy

Estimated

~$10 – $8,750

Neurona TherapeuticsNCT05135091

Observational

Network Neuro-modulation for Mesial Temporal Lobe Epilepsy

In this study, participants will receive unilateral Deep Brain Stimulation (DBS) for treatment of epilepsy, with network-based stimulation targets specifically…

Mesial Temporal Lobe Epilepsy

Estimated

~$10 – $7,500

Nitin TandonNCT05608408